Followers | 14 |
Posts | 306 |
Boards Moderated | 0 |
Alias Born | 01/17/2021 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, January 22, 2022 4:07:05 PM
We need only establish that Amarin "might not" advance our arguments.
Did Amarin pursue the Curfman/Bhatt statistical mistake argument?
Did Amarin pursue the cropped table and other fraud arguments?
Did Amarin file the Rule 60 motion?
The answer to all of these questions is a resounding "No". Accordingly, there is no basis to argue that there was adequate representation.
This is not a sixth amendment right to effective counsel case, which only applies to criminal cases. Adequate Representation for Rule 24 purposes is a construct that exists solely for Civil Rules of Federal Procedure and is very much a different standard than the 6th Amendment Constitutional guarantee.
Yet the argument is being put forth that because Amarin didn’t pursue a statistical argument that was published months after the District Court’s decision this is an example of inadequate representation.
The argument is also being put forth that because Amarin didn’t pursue fraud arguments based on a cropped table missing a legend that only added that the nonsignificant results clearly indicated in the table were calculated using a specific statistical test is an example of inadequate representation.
Finally, the argument is put forth that because Amarin didn’t pursue post-trial relief other than its appeals to the Federal Circuit and the Supreme Court that is an example of inadequate representation.
The above are all considered legal strategies and have little to nothing to do with the Civil Rule construct of adequate representation. And adequate representation refers to the time period and interests during the case-in-chief, not during some post-judgment period, so we can throw the “failure to file a Rule 60 motion” out as grounds altogether.
The case-in-chief was “is there a patent infringement and are the patents valid”? The only issue for this required prong of Rule 24 was whether there was adequate representation of EPADI’s interests DURING the case-in-chief. You can’t say “Amarin lost the case and then didn’t pursue the post-trial relief I favored so that shows there was inadequate representation during the already-concluded case.” You’d need a time machine for that. There is perfect overlap between Amarin’s interests and EPADI’s interests, i.e. valid, non-infringed patents. The fact that Amarin deployed attorneys charging hundreds of dollars an hour to fight for Amarin patents means that EPADI’s interests as shareholders in the Company were well represented. Period.
Disagreeing with a legal strategy does not mean a third party’s interests were not adequately represented. If that was the case then EPADI should have added Amarin’s choice of venue for the trial to their list of grounds demonstrating inadequate representation.
EPADI is basically arguing legal malpractice rather than “adequate representation.” But, even dressed up in a malpractice cloak, this effort would fail. A legal malpractice case seeks to show that the lawyer’s representation caused their client not to prevail in their case and the incompetent representation by the lawyer caused damages to the client. Tough to prove in this case given the the Patent Office originally refused to grant patents because of obviousness.
A common example of legal malpractice is a lawyer missing an important filing deadline that caused their client’s case to get dismissed. Critically, in order to recover financial compensation, it must be demonstrated that the attorney made a mistake and if the mistake never occurred, the client would have prevailed in their case.
So, even under a “legal malpractice” standard, which the Appeals Court is not accepting, it would be impossible to definitively prove that “but for” the missing table legend or a comment by opposing counsel that did not get rebutted, there would have been a different outcome in the trial.
EPADI may not like the results of the court case, but getting the Appeals Court to find there was not adequate representation of EPADI's interests DURING TRIAL will not happen.
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM